Phase II failure rates have not materially improved in twenty years. The evidence that could have changed those decisions existed. The synthesis that would have connected it to the decision did not happen in time.

A translational medicine team working across target validation, biomarker discovery, safety assessment, and indication prioritization is asking questions that span thousands of publications, regulatory documents, internal study reports, and competitive intelligence sources simultaneously. No single search returns what they need. No single scientist can synthesize it at the speed that development programs require.

What those decisions need is an evidence position — a cited, traceable output that shows what the evidence supports, where confidence is high, and where the contradictory findings sit. Decision quality depends not only on generating answers quickly, but on being able to explain why the answer is credible, what supports it, what contradicts it, and what to do next. A reading list does not provide that. A governance committee or a regulatory reviewer cannot work from it.

This eBook examines where that gap appears across the translational medicine function, why general AI tools have been limited in closing it, and what a defensible evidence position looks like when it is built from the full evidence base — with the reasoning trail, citations, and knowledge graph relationships visible throughout.

‍

WHAT'S INSIDE

• Why the synthesis gap persists across Translational Sciences, Biomarkers, Safety, Clinical Pharmacology, and Translational Strategy
• The four structural gaps that limit general AI tools in translational research
• Four customer case studies covering safety characterization, biomarker discovery, PK/PD synthesis, and indication expansion
• How a scientific question becomes a cited, mechanism-grounded evidence package
• Measured outcomes from real programs across global pharm

Download the eBook

‍